DMK
AKBA icon

David M. Knott’s Akebia Therapeutics AKBA Stock Holding History

David M. Knott’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-135,169
Closed -$1.02M – 93
2020
Q1 		$1.02M Buy
+135,169
New +$1.05M 0.65% 28

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

David M. Knott's AKBA Position: Q2 2020 in Review

David M. Knott sold out of Akebia Therapeutics (AKBA) in Q2 2020, closing a stake of 135,169 shares — an estimated $1.02M sold.

David M. Knott first reported a position in AKBA in Q1 2020 and held it in 1 quarter. The position peaked at $1.02M in Q1 2020. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

  • David M. Knott reported no remaining Akebia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • David M. Knott sold 135,169 Akebia Therapeutics shares in Q2 2020, an estimated $1.02M.
  • David M. Knott first reported a position in Akebia Therapeutics in Q1 2020 and held it in 1 quarter.
  • David M. Knott's Akebia Therapeutics position peaked at $1.02M in Q1 2020.
  • 189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on David M. Knott's 13F filing for Q2 2020, filed 12 Aug 2020.